OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis $101.55 -0.80 (-0.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$101.33▼$104.5850-Day Range$91.61▼$104.7152-Week Range$71.51▼$106.82Volume16,707 shsAverage Volume33,662 shsMarket Capitalization$98.15 billionP/E RatioN/ADividend Yield1.07%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address CSL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.33Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth14.75%From $3.05 to $3.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL.Read more about CSL's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently decreased by 94.64%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.08%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 31.14% next year. This indicates that CSL will be able to sustain or increase its dividend.Read more about CSL's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 1.9 News and Social Media Coverage News SentimentCSL has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CSL this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.03% of the stock of CSL is held by institutions.Read more about CSL's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 14.75% in the coming year, from $3.05 to $3.50 per share.Price to Earnings Growth RatioCSL has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCSL has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesJuly 27 at 3:36 AM | americanbankingnews.comCSL Limited (OTCMKTS:CSLLY) Sees Significant Drop in Short InterestJuly 25 at 12:44 AM | theglobeandmail.comCarlisle (NYSE:CSL) Posts Q2 Sales In Line With EstimatesJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 9, 2024 | prnewswire.comCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu SeasonJuly 4, 2024 | globenewswire.comCSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in EuropeMay 30, 2024 | prnewswire.comCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian InfluenzaMay 29, 2024 | msn.comHow much passive income would a $10,000 investment in CSL shares generate?May 20, 2024 | prnewswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 20, 2024 | businesswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 19, 2024 | msn.comBMW M CEO Teases M4-Based 3.0 CSL HomageMay 16, 2024 | investorplace.comCSLR Stock Earnings: Complete Solaria Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comCSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza VaccinesMay 2, 2024 | prnewswire.comRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three SeasonsApril 28, 2024 | msn.comHere is the dividend forecast to 2028 for CSL sharesApril 25, 2024 | investorplace.comCSL Stock Earnings: Carlisle Companies Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 16, 2024 | msn.comHow much do you need to invest in CSL shares for $8,000 in annual dividends?See More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio33.30 P/E Growth1.99Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.31 billion Price / Sales7.37 Cash Flow$3.14 per share Price / Cash Flow32.30 Book Value$18.48 per share Price / Book5.50Miscellaneous Outstanding Shares966,510,000Free FloatN/AMarket Cap$98.15 billion OptionableNot Optionable Beta0.76 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVAstraZenecaNASDAQ:AZNNovartisNYSE:NVSView All Competitors Should I Buy CSL Stock? CSLLY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in CSL Limited: CSL Limited is a leading biopharmaceutical company with a strong global presence in key markets like Australia, the United States, and Europe. The company operates through segments like CSL Behring, CSL Seqirus, and CSL Vifor, offering a diversified portfolio of products in plasma, gene therapies, influenza-related products, and therapeutic areas like iron deficiency and nephrology. Recent performance shows a positive trend with a 52-week performance of 0.0025, indicating stability and potential growth. CSL Limited has a history of research, development, and innovation dating back to 1916, showcasing a long-standing commitment to advancing healthcare solutions. With a current stock price of 98.5 on the record date of 06/30/2024, CSL Limited may present a value investment opportunity for those looking to enter the market at a reasonable price point. Cons Investors should be bearish about investing in CSL Limited for these reasons: CSL Limited's float size is reported as 0, indicating potential liquidity concerns for investors looking to trade shares in the market. Shares shorted in the previous month were 9,100, with a month-to-month change percentage of 1.4615, suggesting some market volatility and short-term risks. Institutional ownership percentage stands at 0, which may raise questions about confidence from larger investment entities in CSL Limited's future performance. Outstanding shares are reported as 0, which could impact market perception and trading dynamics for the company. With an average daily volume of 65,400 shares, investors should consider the trading volume in relation to their investment strategy and risk tolerance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 22, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com. CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed this year? CSL's stock was trading at $97.17 at the beginning of the year. Since then, CSLLY stock has increased by 4.5% and is now trading at $101.55. View the best growth stocks for 2024 here. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CSL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
